Single Ascending Dose Study of ALA-1000

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

May 3, 2021

Study Completion Date

May 3, 2021

Conditions
Opioid-use Disorder
Interventions
DRUG

ALA-1000

Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.

DRUG

buprenorphine sublingual film

ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1

Trial Locations (1)

33016

Innovative Clinical Research, Miami

Sponsors
All Listed Sponsors
lead

Alar Pharmaceuticals Inc.

INDUSTRY